Skip to main content

Table 3 Cox regression model analysis for distant recurrence and disease-free survival

From: The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

Variable

HR (95%CI)

p

DR

 Recurrence Score (50 unit)

3.36 (1.88-6.00)

< 0.001

 FEC-D

1.15 (0.75-1.75)

0.529

  ≥ 4 positive nodes

2.68 (1.73-4.17)

< 0.001

 Tumor size > 20 mm

1.76 (1.12-2.78)

0.015

 SBR grade

 

0.280

  Grade 2

2.29 (0.81-6.48)

 

  Grade 3

2.32 (0.79-6.77)

 

 Ki-67 expression

1.19 (0.75-1.88)

0.453

DFS

 Recurrence Score (50 unit)

2.66 (1.62-4.37)

< 0.001

 FEC-D

1.10 (0.76-1.59)

0.598

  ≥ 4 positive nodes

2.65 (1.82-3.87)

< 0.001

 Tumor size > 20 mm

1.55 (1.06-2.26)

0.024

 Endocrine therapy

0.60 (0.40-0.89)

0.012

 Ki-67 expression

1.17 (0.79-1.74)

0.431

  1. HR hazard ratio, 95CI 95% confidence interval, DR distant recurrence, FEC-D 3 cycles of FEC100 (6 cycles of 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) followed by 3 cycles of docetaxel 100 mg/m2, SBR Scarff–Bloom Richardson, DFS disease-free survival